TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results, Hits Expectations

TriSalus Life Sciences (NASDAQ:TLSI) issued its earnings results on Thursday. The company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35), Zacks reports. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI opened at $5.48 on Thursday. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42. The firm has a 50-day moving average price of $5.38 and a two-hundred day moving average price of $4.73. The firm has a market cap of $167.10 million, a price-to-earnings ratio of -2.16 and a beta of 0.48.

Insider Transactions at TriSalus Life Sciences

In related news, CEO Mary T. Szela bought 5,030 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were purchased at an average cost of $5.03 per share, for a total transaction of $25,300.90. Following the completion of the purchase, the chief executive officer now directly owns 439,249 shares in the company, valued at $2,209,422.47. The trade was a 1.16 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James Emmett Young purchased 24,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were bought at an average price of $5.40 per share, with a total value of $129,600.00. Following the purchase, the chief financial officer now owns 24,000 shares in the company, valued at $129,600. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 54,856 shares of company stock worth $294,608 in the last 90 days. Insiders own 32.80% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on TLSI. Cantor Fitzgerald started coverage on shares of TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $11.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.